CYTK · Company research
Cytokinetics Inc. (CYTK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today - Benzinga | Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance | Cytokinetics, Incorporated (CYTK) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Singapore | Cytokinetics, Incorporated (CYTK) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 13, 2026 | neutral | 0 | 0.6 |
| A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan | A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance | Cytokinetics (CYTK), What Is Behind The Fresh Attention? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Cytokinetics (CYTK) Stock Leaves Valuation Questions Open As MYQORZO Sales Impress - Simply Wall Street | Cytokinetics (CYTK) Stock Leaves Valuation Questions Open As MYQORZO Sales Impress Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance | Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan | Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK | Cytokinetics, Incorporated (CYTK) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance | Cytokinetics, Incorporated (CYTK) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Australia | Cytokinetics, Incorporated (CYTK) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 3, 2026 | neutral | 0 | 0.6 |
| A new study aims to enroll about 400 adults to assess a heart drug in everyday care. - Stock Titan | A new study aims to enroll about 400 adults to assess a heart drug in everyday care. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options. - Stock Titan | At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Why Cytokinetics (CYTK) Stock Is Down Today - Quiver Quantitative | Why Cytokinetics (CYTK) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 28, 2026 | neutral | 0 | 0.6 |
| Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses - Simply Wall Street | Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Cytokinetics (CYTK) Releases Q2 2026 Earnings: Revenue Beats but Losses Persist - Quiver Quantitative | Cytokinetics (CYTK) Releases Q2 2026 Earnings: Revenue Beats but Losses Persist Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| Cytokinetics Prepares for Commercial Rollout Following Regulatory Approvals Across Major Markets - TIKR.com | Cytokinetics Prepares for Commercial Rollout Following Regulatory Approvals Across Major Markets TIKR.com | View source ↗ | TIKR.com | Jun 30, 2026 | neutral | 0 | 0.6 |
| CYTK Forecast — Price Target — Prediction for 2027 - TradingView | CYTK Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 27, 2026 | neutral | 0 | 0.6 |
| Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17% - Trefis | Cytokinetics Stock 6-Day Winning Spree: Stock Climbs 17% Trefis | View source ↗ | Trefis | Jun 22, 2026 | neutral | 0 | 0.6 |
| Why Cytokinetics (CYTK) Is a Buy - The Villanovan | Why Cytokinetics (CYTK) Is a Buy The Villanovan | View source ↗ | The Villanovan | Feb 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.